Rheumatoid arthritis (RA) is a disease where your immune system attacks your own joints, but its effects reach far beyond stiffness and swollen knuckles. Over time, the same inflammation that damages joint tissue can spread to your heart, lungs, blood vessels, eyes, and blood cells. Understanding what RA actually does inside your body helps explain why early, aggressive treatment matters so much.
How RA Attacks Your Joints From the Inside
Every joint is lined with a thin membrane called the synovium, which normally produces a small amount of fluid to keep things moving smoothly. In a healthy joint, this lining is just one or two cells thick. In RA, the immune system floods the synovium with inflammatory cells, including white blood cells called lymphocytes and macrophages. The lining swells to 8 to 10 cells thick, and new blood vessels grow into it to feed the expanding tissue. This overgrown, aggressive tissue is called a pannus.
The pannus doesn’t just sit there. It actively invades and erodes the cartilage and bone at the edges of the joint. Inside the inflamed synovium, your body produces cells called osteoclasts, which are specialized bone-dissolving cells. A signaling molecule called RANKL, released by inflamed tissue and activated immune cells, drives the formation of these osteoclasts in large numbers. The result is permanent bone erosion at the joint margins. Once cartilage and bone are eaten away, that damage cannot fully reverse, which is why catching RA early is so important.
Which Joints Are Affected First
RA typically starts in the small joints of the hands and feet, particularly the knuckles and the joints at the base of the toes. One of its hallmark features is symmetry: if the knuckles on your left hand are swollen, the same joints on your right hand usually are too. No one fully understands why this happens, but one theory involves the nervous system. Nerves branch from the spinal cord and split at each vertebra, one side going left and the other right. Inflammation in a joint on one side may irritate nerves that release inflammatory chemicals to matching joints on the opposite side, creating a feedback loop.
As the disease progresses, it can move into larger joints like the wrists, elbows, shoulders, knees, and ankles. The pattern varies from person to person, but the symmetry tends to persist. Morning stiffness lasting more than one hour, and often several hours, is especially characteristic of RA and helps distinguish it from osteoarthritis, where stiffness typically fades within 30 minutes.
What Happens Beyond the Joints
RA is a systemic disease, meaning the inflammation circulating through your bloodstream can damage organs and tissues that have nothing to do with your joints. These extra-articular effects tend to be more common in people with severe or long-standing disease, but they can appear at any stage.
Heart and Blood Vessels
Chronic inflammation accelerates the buildup of plaque inside artery walls, raising the risk of heart attack and stroke. RA can also cause pericarditis, an inflammation of the thin sac surrounding the heart. Cardiovascular disease is one of the leading causes of the excess mortality seen in RA patients.
Lungs
RA can trigger interstitial lung disease, where inflammation scars the tissue between the air sacs, making it progressively harder to breathe. It can also cause pleuritis, an inflammation of the lining around the lungs that produces sharp chest pain with deep breaths. These lung complications contribute significantly to reduced life expectancy in people with RA.
Eyes
Inflammation can affect the white outer coating of the eye (a condition called scleritis or episcleritis), causing redness, pain, and light sensitivity. RA is also associated with sicca syndrome, severe dryness of the eyes and mouth caused by immune damage to the glands that produce tears and saliva.
Blood Vessels
In people who have had severe RA for more than 10 years, the immune system can begin attacking blood vessels directly, a complication called rheumatoid vasculitis. The affected vessels swell and thicken, restricting blood flow, especially in the hands and feet. This can cause skin ulcers around the fingertips, areas of tissue death, numbness, tingling, and muscle weakness. Though relatively uncommon, vasculitis is one of the more serious complications of long-standing RA.
How RA Affects Your Blood
Many people with RA develop a form of anemia tied directly to their inflammation. The inflammatory molecules circulating in the bloodstream suppress the bone marrow’s ability to respond to signals that normally stimulate red blood cell production. The result is a gradual drop in red blood cells, leading to fatigue, weakness, and shortness of breath. This type of anemia doesn’t respond to iron supplements because the problem isn’t a lack of iron. It improves when the underlying inflammation is brought under control.
The Toll on Bone Density
Beyond the localized erosion at joint surfaces, RA increases the risk of generalized bone loss throughout the skeleton. The same RANKL signaling that drives bone erosion at the joints also tips the balance between bone-building and bone-destroying cells body-wide. Corticosteroids, often used to manage RA flares, compound this problem by further weakening bones. The combined effect raises fracture risk, particularly in the spine, hips, and wrists.
How RA Is Diagnosed
Doctors diagnose RA using a scoring system that considers four factors: how many joints are swollen, whether blood tests show specific immune markers (rheumatoid factor and anti-CCP antibodies), whether blood markers of inflammation are elevated, and whether symptoms have lasted at least six weeks. A score of 6 out of 10 points confirms a diagnosis. Involvement of many small joints and high levels of immune markers push the score up fastest. The key requirement is that at least one joint must have visible swelling that can’t be explained by another condition.
What This Means for Life Expectancy
Before modern treatments, people with RA had roughly double the expected mortality rate over a 10-year period. Treatment has improved that picture considerably, but even with today’s aggressive treat-to-target strategies, studies tracking patients over 10 to 20 years show survival is still about 10 to 13 months shorter than expected compared to the general population. That gap becomes measurable after about a decade of disease. The excess mortality is driven largely by cardiovascular and pulmonary complications, which is why managing inflammation throughout the body, not just in the joints, is a central goal of treatment.
The good news is that the gap has narrowed dramatically. People diagnosed today and treated early with modern therapies face a much better outlook than those diagnosed even 20 years ago. The earlier inflammation is controlled, the less cumulative damage it does to joints, bones, blood vessels, and organs.